In this issue:
ENDURANCE confirms bortezomib-based regimes as the standard of care in transplant-ineligible NDMM
The addition of elotuzumab to lenalidomide/dexamethasone confers a survival benefit in RRMM
Promising results for delay in disease progression with metronomic cyclophosphamide dosing in RRMM
Genetic markers of risk for early disease progression in NDMM
Genome-wide somatic alterations in MM reveal a superior outcome group
Integrated safety profile of selinexor in MM
Teclistamab is an active T cell-redirecting bispecific antibody against BCMA for MM
Lenalidomide and pomalidomide enhance the potency of AMG 701 in preclinical work
Real-world outcomes of bortezomib in elderly Australian patients
COVID-19 in patients with MM
Please login below to download this issue (PDF)